MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...

Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

In the Phase 2 study, the incidence of treatment-emergent adverse events was similar to placebo, and no unexpected safety signals were identified In mUMSARS scores and MRI-based brain volume ...

Alterity appoints neurologist Dr Daniel O Claassen as Chief Medical Advisor Claassen served as coordinating investigator for Alterity’s Phase II ATH434 study in Multiple System Atrophy Appointment ...

Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol - - FDA agreed that a single pivotal Phase 3 trial ...